Swiss life sciences firm Lonza Group AG has agreed to sell its Capsules and Health Ingredients (CHI) division to private equity firm Lone Star Funds for an enterprise value of approximately CHF2.3 billion ($3 billion). The deal structure provides Lonza with CHF1.7 billion in upfront cash while it retains a 40% minority stake in the carved-out business. This divestiture completes Lonza’s strategic pivot to a pure-play Contract Development and Manufacturing Organization (CDMO), freeing capital for its core high-growth platforms. The transaction is a textbook example of value-creating corporate streamlining, allowing the parent company to unlock a higher valuation multiple by focusing on its primary growth engine.
- Target
- Capsules and Health Ingredients (CHI) Division
- Seller
- Lonza Group AG
- Acquirer
- Lone Star Funds
- Transaction Type
- Private Equity Carve-Out / Divestiture
- Enterprise Value
- CHF2.3 Billion / $3.0 Billion
- Upfront Cash Proceeds (to Lonza)
- CHF1.7 Billion / $2.2 Billion
- Seller’s Retained Stake
- 40% Minority Interest
- Seller’s Strategic Driver
- Finalize pivot to a pure-play CDMO
- Announced Date
- Early March 2026
- Expected Close
- Second half of 2026
In a move signaling the final stage of its high-stakes transformation, Swiss life sciences giant Lonza Group AG has agreed to divest its Capsules and Health Ingredients (CHI) division to private equity firm Lone Star Funds. The definitive agreement, announced in early March 2026, values the unit at an Enterprise Value (EV) of approximately CHF2.3 billion (around \$3 billion), marking the culmination of a strategic portfolio review initiated in late 2024. This transaction firmly repositions Lonza as a pure-play Contract Development and Manufacturing Organization (CDMO), freeing capital to reinvest in its core high-growth modalities.
Most “AI for Diligence” tools are lying to you. The truth is, they are just ChatGPT wrappers. Experience what real AI for Diligence looks like, built like Claude Code, but for M&A/ PE Diligence:
đź’Ľ When Claude Code Marries Due Diligence!
For C-suite executives navigating the complex landscape of pharma services, this **life sciences carve-out M&A** is a textbook example of value extraction from non-core assets to fund specialized expansion. The structure of the deal, which includes a significant continuing interest for the seller, reflects both confidence in the asset’s standalone potential and a desire to share in future upside.
Deal Economics: Upfront Proceeds and Retained Upside
The financial structure is noteworthy, providing Lonza with immediate liquidity while maintaining exposure to the future growth trajectory of the ingredients and capsule manufacturing business. Lone Star is acquiring the global business, which operates across three key segments: Hard Empty Capsules, Dosage Form Solutions, and Health Ingredients.
| Metric | Value (Approximate) | Source |
|---|---|---|
| Enterprise Value (EV) | CHF2.3 Billion / \$3.0 Billion | |
| Upfront Cash Proceeds (Lonza) | CHF1.7 Billion / \$2.2 Billion | |
| Lonza Retained Equity Stake | 40% Minority Interest | |
| Total Expected Undiscounted Proceeds | At or above CHF3.0 Billion / \$4.0 Billion |
Lonza has indicated plans to deploy the upfront cash toward funding organic growth, executing bolt-on acquisitions within the CDMO space, and implementing a CHF500 million share buyback program. This financial deployment strategy aligns with maximizing shareholder returns while bolstering its core capabilities.
The Strategic Imperative: Focusing on the ‘Lonza Engine’
The sale of CHI finalizes Lonza’s commitment, first articulated in its December 2024 Investor Update, to focus exclusively on high-value biomanufacturing. Under CEO Wolfgang Wienand, the company has executed a systematic reshuffling, moving away from businesses like micronization and Personalized Medicines to concentrate resources on its three integrated CDMO platforms: Integrated Biologics, Advanced Synthesis, and Specialized Modalities, powered by the “Lonza Engine.” This drive toward a **pure-play CDMO strategy** aims to leverage its deep expertise in complex pharmaceutical modalities and advanced technology execution.
For investment advisors and M&A counsel, this divestiture offers a critical lesson in corporate streamlining: separating a mature, steady-state business allows the parent company to achieve higher valuation multiples by demonstrating tighter operational focus and higher growth potential in its remaining segments.
Lone Star’s Private Equity Thesis: Unlocking Carve-Out Value
Lone Star Funds views the CHI division not as a peripheral unit, but as a global platform with distinct upside potential as a standalone operator. The private equity sponsor sees significant opportunity in applying dedicated capital and strategic focus to a business that Lonza had managed under the constraints of a diversified conglomerate structure.
- Market Positioning: CHI holds leading positions in the Hard Empty Capsules and Health Ingredients markets, sectors underpinned by stable demand from the pharmaceutical and nutraceutical sectors.
- Operational Flexibility: As an independent entity, CHI can pursue unconstrained investment in innovation and operational enhancements, positioning it to accelerate growth that may have been subordinated within the CDMO structure.
- Valuation Arbitrage: The transaction structure, which includes Lonza retaining a 40% stake contingent on Lone Star achieving an initial return hurdle, suggests a shared-risk appetite, common in sophisticated **private equity investment in pharmaceutical ingredients** carve-outs.
Closing Timeline and Industry Implications
The deal is targeted to close in the second half of 2026, pending customary closing conditions and the finalization of the legal separation of CHI from Lonza’s remaining operations. This divestiture marks a definitive shift for Lonza, allowing the market to more clearly value its core CDMO assets. Simultaneously, it introduces Lone Star—a firm active in the sector, having previously been shortlisted bidders for the assets—as a major, focused competitor in the specialized formulation and ingredients supply chain, impacting the competitive dynamics for **contract manufacturing partnerships** going forward.
Sources
fiercepharma.com nasdaq.com longbridge.com contractpharma.com afp.com businesswire.com bloomberglaw.com lonza.com pehub.com lonza.com swissinfo.ch
